ESC launches new concept for driving innovation in cardiovascular research with exclusive support from Boehringer Ingelheim

公司 每日财经网

  • Four grants will be awarded to independent research projects, focused on improving patient outcomes in thromboembolic diseases
  • Grant programme reflects commitment of Boehringer Ingelheim and the ESC to advancing cardiovascular medicine
  • Applications are open from today; ESC Scientific Committee to select grant winners after live presentations by finalists in December 2015

INGELHEIM, Germany — (BUSINESS WIRE) —

The European Society of Cardiology (ESC) today announced the launch of the competitive medical research programme ‘ESC Grants for Medical Research Innovation’, exclusively supported by an independent grant from Boehringer Ingelheim. The programme aims to support research into areas of medical need in cardiovascular medicine. Four grants of up to €400,000 each will be awarded to researchers or clinicians following live presentations by selected finalists to a panel of high profile experts appointed by the ESC.

“We are really excited to support the ESC in launching this unique peer challenge grant concept. We believe this will stimulate exciting new research with the ultimate ambition of improving the lives of patients”, said Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim. “We are encouraging clinicians and researchers to submit their proposals to the ESC.”

“This grant project is a reflection of the ESC’s commitment to encouraging new and innovative research aimed at improving patient outcomes in thromboembolic disease – a leading cause of mortality worldwide,” said Professor Francesco Cosentino, the chair of the programme’s scientific committee. “It is estimated that one in four people die as a result of thromboembolic disease, which causes abnormal blood clotting, and more research into this disorder is urgently needed. We are excited about this initiative because it is a great opportunity to perform important studies aiming to a better understanding of novel therapeutic strategies in this setting. We are now ready to receive applications from around the world for these prestigious grants – until the November 1st deadline – and look forward to announcing the four winners at European Heart House on December 1st following live presentations by all finalists.”

The ESC Grants for Medical Research Innovation website, which includes details about the research categories, applicant eligibility and information about how to submit an entry for the peer challenge, is accessible from today via: www.escardio.org/innovationgrants.

The application deadline is 1 November 2015 and projects awarded funding will be announced in December 2015.

~ENDS~

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the link below for ‘Notes to Editors’: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/29_august_2015_cv.html

View source version on businesswire.com: http://www.businesswire.com/news/home/20150829005015/en/

CONTACT:

Boehringer Ingelheim GmbH
Friederike Middeke

Phone: +49 6132 – 77 141575
Fax: +49 6132 – 77 6601
E-mail:press@boehringer-ingelheim.com
Twitter:http://twitter.com/Boehringer
or
More information
www.boehringer-ingelheim.com

✽本文资讯仅供参考,并不构成投资或采购等决策建议(BW)。

伦敦--(美国商业资讯)--亚洲最大的几家云服务商正采取哪些措施来满足日益增长的AI推理需求?Omdia的最新研究深入分析了AI推理运营所面临的不断演变的挑战,吞吐量、延迟与支持多样化AI模型之间的关键权衡,以及可能的解决方案。该报告详细涵…
旧金山--(美国商业资讯)--Andersen Consulting通过与Rysun的合作强化其在AI和数字化转型领域的能力。Rysun是一家技术咨询公司,专注于帮助企业采用AI技术、实现核心系统现代化,从而提升敏捷性并推动增长。 Rysu…
旧金山--(美国商业资讯)--Andersen Consulting正通过与Exponential Digital Solutions (10xDS)的合作,持续打造其数字化咨询平台。10xDS是一家专注于AI驱动转型及新兴技术的公司。 1…
ANZUPGO(迪高替尼)乳膏现已成为FDA批准的美国首个且唯一的专用于治疗成人中重度慢性手部湿疹(CHE)的药物。1 全世界大约十分之一的成年人受到CHE的困扰,但在此之前,FDA尚未批准针对此类疾病患者的特定治疗药物。2,3 本次获批标…
大模型领域前一阵有个刷屏新闻,现代知名音乐制作人Rick Rubin和Anthropic合作,对《道德经》做了个二创,通过改编老子的原文,写了部《编码之道》(The Way of Code),对AI编码这种新开发方式做了一次哲学诠释,受到社…
  • 科技
  • 2天前
  • 每日财经网
1Globe领导的激进董事会为误导股东的判断公然歪曲纽约法院的裁定,并蓄意隐瞒安提瓜法官上周五拒绝了其立即阻止Prime Success行使投票权的企图 香港--(美国商业资讯)-- Prime Success L.P.(连同其关联方,合称…
  • 公司
  • 6月23日
  • 文传商讯
纽约法院驳回尚珹资本/Prime 紧急禁令救济申请 为股息支付代理公司于2025年7月7日发放每股55.00美元特别现金股息扫清法律障碍 北京--(美国商业资讯)--中国领先的生物制药公司科兴控股生物技术有限公司(Sinovac Biote…
  • 公司
  • 6月23日
  • 文传商讯
—FDA批准的首个用于阿尔茨海默病患者评估的血液体外诊断检测方法— —推出精准、便捷的血液诊断检测将有助于开发和提供更有效的阿尔茨海默病干预措施— 宾夕法尼亚州马尔文和东京--(美国商业资讯)-- Fujirebio今日宣布,该公司的Lum…
  • 公司
  • 5月19日
  • 文传商讯